Category: Top Posts (The “Must Reads”)

Your 2016 Diabetes Conference Calendar!

543862_59738162

After not being able to find a single source for diabetes events and conferences that might be of interest for those who have diabetes and/or advocate for diabetes, I decided to create one. Begun in 2014, it’s become a popular rundown for all diabetes conferences and events that you might be interested in attending.

Ta-da.

Please note that this is U.S.-centric, as I currently live in the United States. (Most of me. My pancreas is currently on the lam somewhere where it cannot be extradited.) However, I have added some international conferences. Most of these can be attended by the hoi polloi, but some do require a medical designation/degree (although a press pass may provide entry). These are regional or national shindigs, not local groups or walks. 

If there is one that I have missed, please notify me at theperfectd [at] gmail [dot] com so I can add it. I will be updating this calendar throughout the year so I suggest you bookmark this page now. (Go ahead. I’ll wait.) 

Click on the title of the conference/event for the website link/additional information.


 

Want to help your fellow people impacted by diabetes by sharing this page on Twitter?

Simply click the birdie and let it automatically tweet this link for you.

Because you rock. 

Tweet: Your 2016 #Diabetes Conference Calendar is here: http://ctt.ec/H5uBi+ thanks to @theperfectdblog - bookmark it! #doc


 

 

January

52nd Annual Clinical Diabetes and Endocrinology Conference (National Jewish Health) January 23 – 26, 2016 – Snowmass, CO

This conference is primarily for endocrinologists, primary care physicians, and other health care professionals with an interest in diabetes, endocrinology and metabolism. That being said, perhaps you want to mention it to YOUR healthcare team?

February

TCOYD (Taking Control of Your Diabetes) February 20, 2016 – Anchorage, AK

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate!

March

63rd Annual Advanced Postgraduate Course (ADA) March 4 – 6, 2016-  San Francisco, CA

A medical conference much like other scientific sessions, leading diabetes experts will give presentations on the latest in diabetes research and care, with small networking sessions thrown in for good measure. Targeted primarily for physicians, physician assistants, nurses, nurse practitioners, dietitians, pharmacists, psychologists, certified diabetes educators, and other health care professionals who care for patients with diabetes and who manage the complications related to this disease.

TCOYD (Taking Control of Your Diabetes) March 5, 2016 – Sacramento, CA 

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate!

15TH Annual Rachel Levine Diabetes & Obesity Symposium March 6 – 9, 2016 – Long Beach, CA

Made possible by the Beckman Research Institute of City of Hope, held in association with the Endocrine Society annual meeting and T1D Exchange. This is the meeting that I wish I could attend, because it covers some amazing topics, including “Lowering the Barrier of Entry and Long-Term Commitment of Pharma in Type 1 Diabetes” and Diabetes Technology (a topic near and dear to many of our hearts!).

The Diabetes UnConference March 10 – 13, 2016 – Las Vegas, NV

The first peer-to-peer idea exchange and support conference for all adults with Type 1 and Type 2 diabetes. Unlike other conferences geared to patients, this conference has no keynotes or research/expert presentations; just discussions facilitated by those with diabetes about topics that may be difficult to have with people who don’t have diabetes!

The Diabetes Collective Pre-UnConference Sessions March 11, 2016 – Las Vegas, NV

Free and open to the general public, sessions will include Dr. Stephen Ponder’s Sugar Surfing, iLet information session, T1D and Pregnancy, policy advocacy, and more. Registration is required. This is for all adults impacted by diabetes. Childcare is not provided.

Bay Area Diabetes Summit March 13th, 2016 – San Francisco, CA

The Bay Area Diabetes Summit is a collaborative effort of medical providers, community organizations, and medical institutions throughout the Bay Area.

The Summit is open to all adults with T1D and their spouses, friends, and significant others, parents, caregivers, and family members of children with T1D. Children with T1D and their siblings can register for a Kids Camp offered by DYF counselors and staff.

April

ENDO 2016 (Endocrine Society) April 1 – 4, 2016 – Boston, MA

Remember that endocrinology is not just about diabetes; it’s about the entire endocrine system. While the annual conference does have diabetes sessions, it’s not the primary focus. There are a few pre-conference sessions focusing on diabetes and a few sessions during the conference.

Carb DM’s 4th Annual Mother-Daughter Weekend April 1-3, 2016 – Dublin, CA

This amazing event is for preteen/teen girls with T1D and their moms. This weekend focuses on T1D from a female perspective and addresses the female cycle from puberty to pregnancy and how it affects and is affected by T1D. Mother daughter communication, healthy body image, talking with peers and significant others about T1D, and more will be discussed.

Children with Diabetes Friends for Life Fall Church 2016 April 8 – 10, 2016 – Falls Church, VA

Three tracks will take you through technology, policy advocacy, Nightscout, and living with diabetes in this star studded conference near the nation’s capitol. Child care is available.

TCOYD (Taking Control of Your Diabetes) April 16, 2016 – Memphis, TN

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate!

TCOYD (Taking Control of Your Diabetes) April 30, 2016 – Honolulu, HI

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate!

GTC Diabetes Summit 2016 April 25-27, 2016 – Boston, MA

Got $2495? Then this conference is for you.

According to the website, that $2495 will get you research, partnership opportunities and network with academia, venture capital, government, small/medium size biotech, big pharma and healthcare organizations. The summit includes the Diabetes Drug Discovery and Development Conference, dealing with the clinical side of things. The Diabetes Partnering & Deal-Making Conference dives into opportunities for partnerships, funding, licensing, and the financial bits of it all.

May

TCOYD (Taking Control of Your Diabetes) May 21, 2016-  Washington, DC

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate! (They’re missing the entire southeastern portion of the United States.)

31h Annual Clinical Conference on Diabetes (ADA) May 26 – 29, 2016,  Ponte Vedra, FL

While not patient-centric, attendees will hear “cutting-edge research translated into clinical practice”. The 30th Annual Clinical Conference is designed specifically for primary care and diabetes specialty physicians, doctor of osteopathy, podiatrists, pharmacists, physician assistants, nurse practitioners, nurses, psychologists and dietitians, certified diabetes educators and other health care professionals who care for patients with diabetes, at risk for diabetes, and who manage diabetes related complications.

AACE 25th Annual Scientific and Clinical Congress (American Association of Clinical Endocrinologists) May 25 – 29, 2016 Orlando, FL

Endocrinology encompasses more than just diabetes. There will be many sessions on diabetes and other endocrine issues at this conference for medical professionals.

June

Students With Diabetes National Conference June 3 – 5, 2016 – Safety Harbor, FL

A conference for young adults aged 18 – 30 from all over the country who want to learn about the latest in technology, research, and more from many amazing speakers.

 76th Scientific Sessions (ADA) June 10-14, 2016 – New Orleans, Louisiana

The “big” medical conference. While not specifically designed for the layperson with diabetes, many advocates do attend and sit in on sessions. Many study results are presented. We expect to see some major announcements this year.

Western Slipstream (Connected in Motion) June 17 – 19, 2016 – Canmore, Alberta, Canada

If you’re sporty and love The Great White North (to which the latter I can wholeheartedly attest), then go hang out with other Type 1s and do some athletic stuff. Connected In Motion is an amazing organization for adults with Type 1 diabetes.

TCOYD (Taking Control of Your Diabetes) June 18, 2016-  San Antonio, TX

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate!

2016 ConnecT1D Retreat June 25 – 26, 2016 – Seattle/Bainbridge Island, WA

The 2016 ConnecT1D Retreat is a 1-2 Day retreat for adults, teens and young adults with Type 1 Diabetes (T1D). It’s a weekend to share, learn and laugh with others who face the demands- and oddities- of the daily grind that is T1D.

July

Friends for Life July 5 – 10, 2016 (Children With Diabetes) – Orlando, FL 

This is the de facto gold standard for any family with diabetes. It’s being held this year at the Orlando World Center Marriott.

Room rates are $169 + tax. This rate is available 3 days before and after the conference for those families who might want to extend their vacation. Self-parking is $18/day, with a 50% discount if you are in the room block.

Larger Suites may be reserved for hospitality events or entertaining, subject to availability. Suites are also available for larger families, again subject to availability. There are different types of suites and they have different prices; please contact the hotel directly for availability and pricing.

For housing reservations, call Marriott reservations directly at (888) 789-3090 or use Marriott’s Online Reservation System. If you are calling, be sure to say you are with the Children with Diabetes Friends for Life conference. The Children with Diabetes room block is available on a first-come, first-served basis. Please note that you are only in the CWD room block – and only have the perks of being in the room block – if you make reservations through these phone numbers or website.

2016 Practical Ways to Achieve Targets in Diabetes Care July 14 – 17, 2016 – Keystone, Colorado

While not a patient conference, worth taking a look at to see what’s being discussed. “This course is designed to help healthcare providers caring for patients with diabetes, including but not limited to, endocrinologists/diabetes specialists, internists, pediatricians, family physicians, physician assistants, medical residents, fellows, nurse practitioners, nurses, dietitians and certified diabetes educators.”

Hodia DTreat 2016 July 15 – 17, 2016 – Boise, ID

Hodia DTreat is a diabetes retreat for young adults with T1 and their support persons aged 18-30 years old! Over the weekend you will have the opportunity to form relationships with others who get it, and talk truth about the issues facing people your age with T1D.

August

TCOYD (Taking Control of Your Diabetes) August 27, 2016 Corning, CA

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate!

AADE 16 (American Association  August 12 – 15, 2016 San Diego, CA

This is a conference for diabetes educators but patients are welcome to attend as well. The focus is on fostering better communication between patients and providers and helping educators to become integral parts of a patient’s care.

September

The Diabetes UnConference September 9 – 11, 2016 – Atlantic City, NJ

The first peer-to-peer idea exchange and support conference for all adults with Type 1 and Type 2 diabetes. Unlike other conferences geared to patients, this conference has no keynotes or research/expert presentations; just discussions facilitated by those with diabetes about topics that may be difficult to have with people who don’t have diabetes!

Summer Slipstream (Connected in Motion) September 16 – 18, 2016 – Ontario, Canada

If you’re sporty and love The Great White North (to which the latter I can wholeheartedly attest), then go hang out with other Type 1s and do some athletic stuff. Connected In Motion is an amazing organization for adults with Type 1 diabetes.

Friends for Life Anaheim 2016 September 16 – 18, 2016 – Anaheim, California 

Registration has not opened yet. This will be updated when the registration link becomes available.

52nd EASD Annual Meeting  (European Association for the Study of Diabetes) – Munich, Germany

This is the European “big” medical conference, much like ADA’s Scientific Sessions.

October

Slipstream in the US (Connected in Motion) October, 2016 – TBA

Connected In Motion is an amazing organization for adults with Type 1 diabetes and they’ll be coming to the US to do something athletic. At this time, no further information regarding dates, place, or cost has been released, but by bookmarking this page, you can come back and check!

TCOYD (Taking Control of Your Diabetes) October 1, 2016 – San Diego, CA

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate!

Canadian Diabetes Association CDA/CSEM Professional Conference October 26 – 29, 2016 Ottawa, Ontario, Canada

The “big” medical conference in Canada. While not specifically designed for the layperson with diabetes, many advocates do attend and sit in on sessions.

November

TCOYD (Taking Control of Your Diabetes) November 19, 2016 –  Orlando, FL

TCOYD is a one-day program with tracks for both Type 1 and Type 2 individuals (and their friends and family, of course). Those who attend will have opportunities to learn about the latest tools, tips, techniques, and technology to help live healthier lives with diabetes. What I love about this program is that it was founded and is run by physicians who have intimate knowledge of diabetes; they have the disease! Many of the speakers also have Type 1 or Type 2 diabetes, so it’s not as if it’s a “do as I say and not as I do, because I don’t have a clue” program. If you have one coming to your area, you’re fortunate!


 

Want to help your fellow people impacted by diabetes by sharing this page on Twitter?

Simply click the birdie and let it automatically tweet this link for you.

Because you rock. 

Tweet: Your 2016 #Diabetes Conference Calendar is here: http://ctt.ec/B6b7I+ thanks to @theperfectdblog - bookmark it! #doc


 

PLEASE NOTE:

I did not include “invite only” conferences.

As always, there are bound to be more opportunities to meet other people with diabetes, learn about the disease, and advocate. These are just a few. As I hear of more, I’ll post them here. And if you’re interested in getting your national/regional event on the list, please contact me at theperfectd [at] gmail.com and let’s talk.

Dear JDCA (Juvenile #Diabetes Cure Alliance) Part Two

hands-talking-1311915-640x480If you have no idea what’s going on, please read Dear JDCA Part One.

It will bring you up to speed (as quickly as 2500 words can), giving you the information regarding what the Juvenile Diabetes Cure Alliance thinks are the most likely “practical cures” for people with Type 1 diabetes and why their petition demanding JDRF and ADA to commit 30% of donations to “cure research” isn’t doing anything to help the diabetes community except cause deep fractures amongst us.

Part One covered the transplantation “practical cures” that JDCA believes we should all support with the intent to have these cures available by 2025.

Part Two below covers the devices and the immune system manipulation options they highlight.

Quick Recap

The Juvenile Diabetes Care Alliance states that they want a “practical cure” by 2025. JDCA’s Four categories of a “practical cure”:

  • Islet cell transplantation
  • A device that mimics the pancreas
  • Glucose-responsive insulin (“smart insulin”) ***Please note that none of the potential practical cures are of this type.***
  • Modification of the immune system (blocking, balancing, and/or retraining)

Every year, JDCA issues a report that tells potential donors which “practical cures” are more likely to pull ahead. Here are the 2014 “Potential Practical Cure Solutions,” found in the JDCA State of the Cure report. (2015 hasn’t been published yet, but expect it in the fall as in previous years).

For each,  I will provide you the basic info into what it is, where this is in terms of “potential” release into the community and who is funding it.

JDCA’s 2014 Potential Practical Cure Solutions (Part 2)

Device

Bionic Pancreas (iLet)

Boston University

– Boston, MA

What it is: 

Engineers from Boston University have developed a bionic pancreas system that uses continuous glucose monitoring along with subcutaneous delivery of both rapid-acting insulin (to lower blood glucose) and glucagon (to raise blood glucose) as directed by a computer algorithm. The bionic pancreas automatically makes a new decision about insulin and glucagon dosing every five minutes; that’s 288 decisions per day, 7 days per week, 365 days per year. (Artificialpancreas.org)

Where it is in the pipeline of “practical cure”:

According to Clinical Trials.gov, Phase III clinical trials will begin soon, with an estimated completion date of August, 2016. 80 participants will be in this trial. All clinical trials to this date have had favorable results.

If the pipeline is followed, commercialization is to be expected by 2018. The major issues will be funding and the FDA approval of stable glucagon provided by Xeris Pharmaceuticals.

 

Who is funding this “practical cure”?

Drs. Damiano and Russell do not work for a privately funded company. They work for universities. Funding is obtained through NIH grants and generous donations from private donors. JDRF did fund a portion of this research. 

There is currently no investment funding for future commercial agreement. Funding is being obtained through donations made through Boston University and Massachusetts General Hospital, private grants, and potentially NIH.

This is one “potential cure” that is fueled by direct donations from the general public.

If you are interested in donating to the Bionic Pancreas (iLet), you can do so here. 

If you want to learn more about the iLet, click here.


Modification of the immune system

BCG

Faustman Labs (Massachusetts General Hospital)

-Boston, MA

What it is: 

The BCG Human Clinical Trial Program is testing Bacillus Calmette-Guérin (BCG), an inexpensive generic drug, as a treatment for advanced type 1 diabetes.

…current research focuses on discovering and developing new treatments for type 1 diabetes and other autoimmune diseases, including Crohn’s disease, lupus, scleroderma, rheumatoid arthritis, Sjögren’s syndrome, and multiple sclerosis. (Faustman Lab website)

Where it is in the pipeline of “practical cure”:

A Phase II clinical trial which will last five years is being launched.

In the phase I clinical trial, which was published in the August 8, 2012, issue of PLOS Medicine, two injections of BCG spaced four weeks apart led to temporary elimination of diabetes-causing T cells and provided evidence of a small, transient return of insulin secretion. The phase II clinical study will include more frequent dosing over a longer time period to determine the potential of repeat BCG vaccination to ameliorate the autoimmune state and improve clinical parameters such as HbA1c, a marker of average blood sugar control. (Eureka Alert)

Here is the Clinical Trials.gov posting for the Phase II Clinical Trial. Please note that this is a double blinded trial. Neither the investigator nor the participant will know if they are being administered the BCG vaccine or saline injections over 5 years. 150 participants will be selected.

Earliest results will be in 2020. Please also be aware that a Phase III Clinical Trial must be conducted after successful results are shown, which can delay commercialization by several years if the Phase II Clinical Trial results show promise.

Who is funding this “practical cure”?

The Lee Iacocca Foundation gave Faustman Labs $10 million dollars initial funding for her Phase I trials and has also committed funding to Phase II trials. Faustman Labs estimates that Phase II trials will cost $25.2 million dollars.

This is one “potential cure” that is fueled by direct donations from the general public.

If you are interested in donating to Faustman Labs, click here. 

Note: Mike Hoskins of DiabetesMine/Healthline did a recent interview with Dr. Denise Faustman in March, 2015. It’s an important read.  During the interview, Dr. Faustman mentions that neither JDRF or Helmsley Charitable Trust has funded her, but that NIH, private supporters, Lee Ioacocca and others have chosen her research as their “practical cure.”


TOL-3021

Tolerion, Inc.

-Portola Valley, CA

What it is: 

TOL-3021, is a novel reverse vaccine that induces tolerance to the type 1 diabetes specific auto antigen proinsulin and thereby reduces disease activity.

Unlike conventional vaccines, which act to stimulate the immune system, the reverse vaccine TOL-3021 is designed to selectively suppress specific elements of the immune system that are inappropriately activated in type 1 diabetes. TOL-3021 contains an engineered DNA plasmid that expresses proinsulin, which is associated with the autoimmune-caused destruction characterizing type 1 diabetes.(Tolerion website)

Where it is in the pipeline of “practical cure”:

In 2013, a press release regarding TOL-3021 stated:

The Phase 2 study results reported in today’s edition of Science Translational Medicine1 demonstrated that TOL-3021 preserved pancreatic beta-cell function while reducing destructive disease-specific T-cell activity in patients with type 1 diabetes.

These promising Phase 2 data indicate that TOL-3021 may stop the destruction of pancreatic beta cells and improve the long-term outlook for patients with type 1 diabetes, even in adults with long-established disease. Based on these results, we are eager to test TOL-3021 in a larger trial with longer dosing beyond 12 weeks, and to assess whether it might slow or stop disease progression entirely in younger patients when administered before large numbers of beta calls have been destroyed.

Nothing in regards to clinical trials has been published since 2013. In 2013, an article regarding the Stanford researchers who conducted this trial stated:

There are caveats with the trial. For one, the vaccine must be studied in more humans and is years away from being considered for Food and Drug Administration approval. What’s more, in the study, the vaccine’s benefits tailed off a few weeks after its 12-week dosing schedule was stopped.

I have yet to find another announcement regarding a Phase III clinical trial or anything regarding this “practical cure” since 2013. 

Who is funding this “practical cure”?

Dr. Lawrence Steinman, the Stanford researcher who, along with other researchers involved with this project, founded Tolerion. Here’s what he had to say regarding funding:

I can’t give enough praise to Bayhill’s investors, the JDRF (formerly the Juvenile Diabetes Research Foundation) and well-known VCs on Sand Hill Road and the Bay Area.

(When I dug a little deeper, I found that the original name of this drug was BHT-3021 and the trial was funded by… JDRF in collaboration with Bayhill Therapeutics.)

Rights to the reverse vaccine technology and associated product pipeline have been licensed to Tolerion by Stanford University.

There is no public donation funding being requested.


Cyclosporine Omeprazole/Lansoprazole

Perle Bioscience

-Charleston, NC

What it is: 

Cyclosporine is a well-known immunosuppressant given as an anti-rejection medication after organ transplantation and for treatment of RA (rheumatoid arthritis) or psoriasis.

Lansoprazole is a proton-pump inhibitor. You might know it by its brand name: Prevacid.Omeprazole is also a proton-pump inhibitor. (Brand name: Prilosec.) It decreases the amount of acid in the stomach and is commonly used in treating heartburn and GERD (reflux).

In 2013, Chris Leach of Insulin Nation wrote an incredibly informative article about Perle Bioscience and their “practical cure”.  He gave a better overview than I ever could about this so I encourage you to read his work.

Where it is in the pipeline of “practical cure”:

On June 23, 2015, Perle Bioscience announced that a Stage 3 clinical trial was beginning with their drug combination – PRL001. Except…

This Phase III clinical trial is not for individuals with long-standing Type 1 diabetes. According to the ClinicalTrial.gov information, this trial is for newly diagnosed Type 1 diabetics aged 10 – 20 years old. The trials will not be conducted in the U.S.

For those with diabetes diagnosed more than 12 weeks ago, the only clinical trial data listed on ClinicalTrial.gov, there is simply a “This study is not yet open for participant recruitment.” It’s last update was October 3, 2013.

Perle Bioscience’s website gives this information regarding its pipeline:

PRL001

PRL001 consists of the combination of two previously approved therapeutic agents, each yielding their specific response on the body. In Vivo animal studies, the first product inside of PRL001 causes the regeneration of the patients own insulin producing pancreatic beta cells to start growing again. The second part of PRL001 lowers the body ability from re-attacking the newly formed insulin producing cells to essentially put the pancreas back to how it was functioning prior to diabetes. Both agents are taken orally and no injections are needed for this product. Perle Bioscience, Inc. holds the issued and pending US and IPC patents (see below for patents) for the new use of these agents in treating diabetes. PRL001 is starting multi-center Phase 3 human trials in early 2015.

PRL002

PRL002 is a novel peptide developed by Perle Bioscience, Inc., where in current in vitro and in vivo studies, is showing signs of high levels of regeneration of insulin producing pancreatic cells. PRL002 is made up of our novel Beta Regeneration Agent for Diabetes (BRAD) peptides. Currently PRL002 is in animal trials with the hope to have an IND application to the FDA in early 2016. Our hope is that PRL002 will be used for both type 1 and type 2 diabetes. Please sign up for our newsletter to stay up to date on our progress (signup from the bottom of any page).

There is no mention of the Phase III clinical trial for individuals with “existing Type 1 diabetes” on Perle Bioscience’s website. 

Who is funding this “practical cure”?

According to Motley Fool:

Perle is a privately held company, so no investments can be made here as of yet.


Tianhe Stem Cell Biotechnologies

Stem Cell Educator Therapy

-China

What it is: 

“Stem Cell Educator therapy” is the innovative technology developed by Dr. Yong Zhao that uses stem cells drawn from human cord blood to targets autoimmune diseases. Currently, Tianhe is focusing on the application of Stem Cell Educator therapy in diabetes. Our clinical data provide powerful evidence that Stem Cell Educator therapy can balance the immune system and lead to the regeneration of islet beta cells and improve metabolic control in long-standing diabetic subjects. This groundbreaking technology is taking steps towards the ultimate cure of diabetes and revolutionizing the treatment of other autoimmune-related diseases.(Tianhe website.)

Where it is in the pipeline of “practical cure”:

Clinical Trials.gov gives this information: Stem Cell Educator Therapy in Type 1 Diabetes was last updated in November, 2013 and is still stating that it is recruiting participants in China and Spain. Expected completion was September, 2014.

No additional information regarding trials and a “practical cure” has been listed on the Tianhe website. The latest clinical trial information discusses Stem Cell Educator Therapy for hair regrowth in Alopecia Areata patients. (April 22, 2015)

Who is funding this “practical cure”?

The Chinese government, according to the sponsorship information provided on Clinical Trials.gov. The Tianhe website is looking for investors, stating this as an enticement:

A huge marketing opportunity due to the global prevalence of diabetes: For instance, the total number of Americans living with diabetes will increase by 64% in 2025. Annual Medicare cost will increase by 72%, with $514 billion/year (72nd ADA report).

There is no request from the general public for donations.


Previous JDCA “Practical Cures”

file-1-3-1237622-640x640JDCA has published three reports, talking about the “cure” and which projects they believe fall under the guidelines. I’ve focused on the 2014 report (which is the latest), but what about 2013? 2012? (They began in 2011.)

2013

In 2013, here’s what they said were practical cures paths, because they were in human trials:

Still going…

Diabecell (Phase II) – I’ve listed the latest in Part 1.

Tianhe Stem Cell Educator Therapy (Phase II) – I’ve listed the latest above.

BCG (Phase II recruiting) – I’ve listed the latest above.

ViaCyte (Phase I) – I’ve listed the latest in Part 1.

Off the list in 2014…

Sitagliptin/Lansoprazole (Phase II) Note: collaborator listed on ClinicalTrials.gov is JDRF. Status listed now as “The recruitment status of this study is unknown because the information has not been verified recently. )

Monolayer Cellular Device (Phase 1) According to ClinicalTrials.gov, this study is still recruiting patients for one location in Belgium, but JDCA has dropped it from the 2014 list of practical cures.

2012

In 2012, here’s what they said were practical cures paths:

Still going…

Diabecell (Phase II) – I’ve listed the latest in Part 1.

BCG (Phase II recruiting) – I’ve listed the latest above.

Off the list in 2013 and 2014…

Sitagliptin/Lansoprazole

Monolayer Cellular Device

ATG/GCSF – This Phase II clinical trial  is no longer recruiting patients but is active (meaning they got enough participants). The work is still ongoing, but if you read the criteria, it was modified to say that the participants must have been diagnosed between 1 and 2 years before the start of the study, taking out the possibility for those with long-standing Type 1 to participate. The trial is called: Reversing Type 1 Diabetes After it is Established and is being run by University of Florida with grants from the Helmsley Charitable Trust and Genzyme.


My Scorecard for 2014 Practical Cures

Based on what JDCA says are “practical cures” and what I’ve researched, here is the likelihood that they will become commercially available by JDCA’s 2025 “deadline.”

Transplantation

VIACYTE – Phase I/II clinical trial right now. Estimated commercialization date of this product if Phase I/II is successful, a Phase III trial is conducted and successful and proceeds to FDA approval? Unlikely by 2025.  
DIABECELL – Phase I/IIa completed. No Phase III clinical trials listed in ClinicalTrials.gov. Estimated commercialization date of this product if there is a Phase III trial and it proceeds to FDA approval? Unlikely by 2025.
ßAIR BIO-ARTIFICIAL PANCREAS – Phase I/II clinical trial right now. Estimated commercialization date of this product if Phase I/II is successful, Phase III happens and is successful and proceeds to FDA approval? Unlikely by 2025.

Device

BIONIC PANCREAS (iLET) – Phase I/II completed and Phase III beginning soon. Estimated commercialization date of this product if  Phase III proceeds to FDA approval and Xeris Pharmaceuticals gets FDA approval for stable glucagon? Likely by 2018 (2019 if you’re hedging bets.).

Modification of the Immune System

BCG – Phase II clinical trial being launched, lasting five years. Estimated commercialization date of this product if Phase II and Phase III is successful, proceeding to FDA approval? Unlikely by 2025.
TOL-3021 – Phase II clinical trial completed, with results showing the benefits did not last longer than the 12 week dosing period. There are no Phase III clinical trials list. Unlikely by 2025.
CYCLOSPORINE/LANSOPRAZOLE – Phase II completed. No clinical Phase III clinical trial listed on clinicaltrials.gov for patients with existing Type 1 diabetes. Unlikely by 2025.
STEM CELL EDUCATOR THERAPY – Phase II clinical trial listed in 2013 and still recruiting. Estimated commercialization date of this product if Phase I/II is successful, a Phase III trial is conducted and successful and proceeds to FDA approval? Unlikely by 2025.  

Conclusion to this LONG Part 2…

paper-numbers-1236363-639x426What one organization thinks is a  cure isn’t always a cure to you. It’s easy for JDCA call out an organization for not doing enough for what they think is “cure research.”
It’s much more difficult to do so when you realize that everyone has a different (and in JDCA’s reports, showing an ever changing) idea of what a “practical cure” would mean. 
What is practical in 2012, 2013, and 2014 may not be practical in 2015. JDCA kept mentioning DRI’s BioHub, but never put it on the top list of their “practical cures,” but yesterday’s announcement that the first human subject to be implanted with the BioHub is off insulin. (Time will tell is this is successful in the long-term, but JDCA didn’t consider this a donation priority.)
What about “smart insulin?” What about the other closed loop AP trials? What about…. something we haven’t thought of yet? We don’t know what the young researchers in five years will present to major diabetes organizations (or the general public). Seed money comes from these large diabetes non-profits to new researchers who seek out grants to get them off the ground. What happens to these researchers if they don’t get the seed money?
Nothing. Literally. 
JDCA is cherry-picking (and finger pointing, but to what end remains to be seen). It’s their right and I’ve learned a lot about the different avenues to a “practical cure. ” (Hat tip to JDCA for sending me down the rabbit hole. I’m certainly better educated for it.)
We are ALL cherry-picking. It’s our right. But do it by doing the research and making smart, educated choices.
We are all in this together, despite differences in opinions about what a cure entails, who is going to provide it, and who should fund it. And most importantly, who speaks for you. (Here’s a hint… it’s not me or JDCA.) It’s my hope that you learned something about “cure research” and where YOU can get your information about cure pipelines so you can speak for yourself.
Thank you for reading all the way to the end. 

Dear JDCA (Juvenile #Diabetes Care Alliance)… Part 1

hands-talking-1311915-640x480Over the past few weeks, I’ve been seeing infographics produced by the Juvenile Diabetes Care Alliance (JDCA) regarding “cure research” and major diabetes organizations.

The infographic is not flattering, and like everything related to statistics, not entirely truthful. (JDCA even admitted in a post on FB that they made some “judgment calls” in their numbers.)

At first, I ignored the repeated posting in Facebook groups of how JDRF and ADA have not done enough to find a cure for us, but after a while, the bashing became nothing but a “I hate these organizations and I’ll never donate to them again. How dare they take our money and do nothing.

I spoke up and reminded individuals in those groups that there are MANY ways to use the donations raised through walks and rides and other fundraising opportunities, but that ALL of the donations were being used to help people with diabetes, whether it be for research or for support. (And I also reminded them that there was a marked absence in this infographic of where one should be donating…)

My opinion voiced, I went on my merry way, living my life with diabetes, until I got an unsolicited email yesterday from someone claiming to be an employee of JDCA, asking me to promote, on my blog and through social media channels, their petition to the major diabetes non-profits, DEMANDING that JDRF and ADA use 30% of all donations for “practical cure research” through my blog.

Thank you for the invitation, JDCA. I’m going to pass.

Instead, I’m going to take my blog and use it took peek into what your privately funded non-profit, founded by the CEO of Activision Blizzard Entertainment (and a parent of a child diagnosed with Type 1 diabetes at the age of 2) wants us to focus on, rather than telling us what JDRF and ADA isn’t doing.

magnifying-glass-1240025-639x397As I began writing this and hit 2500 words, I realized that this needs to be digested in more than one sitting, so I’m splitting this into 2 blog posts. (Mostly, because no one except masochists read 2500 words of my blog at a time and because I WANT YOU TO READ ALL OF THIS IMPORTANT AND UNBIASED INFORMATION.) Today, I’m covering just the Transplantation “practical cures” and you’ll get the others tomorrow in Part 2.

Juvenile Diabetes Research Alliance

According to a WSJ article, Mr. Kelly’s family foundation, the Brian and Joelle Kelly Family Foundation, has donated $1 million dollars (as of  the 2013 article stated) to JDCA. The goal of JDCA is to help donors “become educated about charities that are focused on a “practical cure” for Type 1 diabetes.

Note: Hey, I have no problem with the fact they have spent $1 million dollars to create a “watchdog” organization. They could have spent it on a boat or a house or funding one of their “practical cure” projects. If you’ve got money, you also have the right to spend it as you see fit. I also believe in watchdog organizations, as long as you provide factual, correct, public-facing information.

“Practical Cure”

The Juvenile Diabetes Care Alliance states that they want a “practical cure” by 2025. For their definition, a “practical cure” meets the following four criteria:

  • Minimal Monitoring (checking BGs less than once per week and a A1C between 5-7%)
  • Being able to sleep without worrying (about hypoglycemia or hyperglycemia)
  • Being able to eat whatever one wants without having to evaluate carbohydrate intake
  • Minimal side effects, understanding that some insignificant side effects are “acceptable”

Sounds reasonable, right? I’m all for that, because that elusive “don’t have to do anything ever again, it’s like magic and you don’t have to think about diabetes for the rest of your life” is a dream.

It then begs the question: What is JDCA’s idea of a practical cure?

JDCA’s Four Ideas of a “practical cure”:

  • Islet cell transplantation
  • A device that mimics the pancreas
  • Glucose-responsive insulin (“smart insulin”)
  • Modification of the immune system (blocking, balancing, and/or retraining)

Again, sounds reasonable, right? Some of these practical cures are beginning to look like they may not make the 2025 timeframe cut-off, but you never know, right?

Every year, JDCA issues a report that tells potential donors which “practical cures” are more likely to pull ahead. Here are the 2014 “Potential Practical Cure Solutions,” found in the JDCA State of the Cure report. (2015 hasn’t been published yet, but expect it in the fall as in previous years) – and I’m going to show you where the funding is coming from. 

JDCA’s 2014 Potential Practical Cure Solutions

These solutions are broken down by type of “practical cure” and gives you the basic info into what it is, where this is in terms of “potential” release into the community and who is funding it. (For my own personal curiosity, I have delved deeper into some than others.) As a reminder, Part 1 is ONLY transplantation. Part 2 is the rest of the “practical cures.”

Transplantation

VC-01

(ViaCyte – a privately held, for profit company)

-San Diego, CA

What it is (straight from ViaCyte’s website):

ViaCyte’s innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01™), with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device (Encaptra® drug delivery system). Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte’s goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence.

Where it is in the pipeline of “practical cure”:

ViaCyte, Inc. announced in July 2014 that it had filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes, and in August 2014 the IND was accepted, allowing clinical testing to commence. This first-in-human trial will evaluate the safety and efficacy of ViaCyte’s VC-01™ product candidate, a stem cell-derived, encapsulated cell replacement therapy. ( Viacyte’s website)

They are in Phase I/II clinical trials at two locations, with an expected trial end date of August, 2017 with an estimated enrollment of 40 participants. Note: According to Wikipedia, “The percentage of Phase II trials that proceed to Phase III, as of 2008, is 18%.” Estimated commercialization date is unknown, but safe to say more than five years off.

Who is funding this “practical cure”?

JDCA forgets to include this:

JDRF is a major funder. 

ViaCyte has received substantial financial support from both the California Institute for Regenerative Medicine (CIRM) and JDRF. (Direct from the front page of ViaCyte website.)

Additional funders/partners include: Cellular Dynamics International, Invitrogen, now a part ofLife Technologies, Nestlé Institute of Health Sciences, Seventh Framework Programme, StemCell Technologies, Johnson & Johnson Development Corporation, Sanderling Ventures, Asset Management, BD Ventures LLC, Hospira, Inc., Portage Venture Partners, and The Clayton Foundation.

Note: What happens when/if it becomes commercially available? Janssen has signed an agreement with ViaCyte.

The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01™ combination product that ViaCyte is developing for type 1 diabetes. This right will continue through the initial evaluation of clinical efficacy of VC-01.  ViaCyte received $20 million from Janssen and Johnson & Johnson Development Corporation (JJDC).  The payment included a rights fee and a note convertible into equity at a later date.  JJDC has been a long-standing investor in ViaCyte.


 DIABECELL

(Living Cell Technologies – a multinational for-profit in a joint venture with DOL)

– New Zealand, Japan

What it is:

DIABECELL is an insulin-producing cell product derived from pigs for the treatment of type 1 diabetes. These islet cells are self-regulating and efficiently secrete insulin in the patient’s body.

The treatment involves introducing encapsulated pig cells into the patient’s abdomen in a simple laparoscopic procedure. Living Cell Technologies’ unique proprietary encapsulation technology prevents the islet cells from being attacked by the patient’s immune system. This allows the use of cell therapies without the need for co-treatment with drugs that suppress the immune system, which often have negative side effects.

Where it is in the pipeline of “practical cure”: 

To date, a total of 46 patients have taken part in clinical trials of DIABECELL. The goals of these trials have been to find the optimal dose required for DIABECELL and to obtain early indication of its effectiveness in controlling type I diabetes. These trials showed that DIABECELL has the potential to significantly reduce the number of unaware hypoglycaemic events that people living with Type I diabetes experience, whilst also reducing their insulin dose and not experiencing a rise in HbA1c.

DOL is now preparing for a larger Phase II/III study to more fully determine the frequency and extent of this benefit.(Taken from Diatranz Otsuka Limited (DOL) website.)

The clinical trial results for DIABECELL are located here.

Highlights:

Phase I/IIa safety study (Russia) – Two out of the eight trial patients discontinued insulin injections for up to 32 weeks. (The assumption being that after 32 weeks, they resumed insulin injections.)

According to Seeking Alpha, an investment media company: “Mostly, the results are more modest involving decreased insulin injections and significant reduction in unaware hypoglycemic events.”

There are currently no clinical trials offered through Clinical Trials.gov (a global trial locator). 

Who is funding this “practical cure”?

LCT is an Australian for-profit company with headquarters and operations located in New Zealand. They have a joint venture with Diatranz Otsuka Limited (DOL). In June of 2015, DOL announced:

Diatranz Otsuka Limited (DOL), is to concentrate its research and development activities in supporting the development of DIABECELL® in the United States. As a consequence, research, development and manufacturing of DIABECELL in New Zealand will cease and there will be a reduction of staff at DOL’s headquarters in Auckland.

Otsuka Pharmaceutical Factory, Inc. (OPF), DOL’s 50% shareholder, is full sponsor and funder of the US program, operating under and exclusive license from DOL for US development and commercialisation of DIABECELL. Since securing the license, OPF has made positive progress, establishing a solid partnership framework for the US development.

DOL’s know-how, research to date and clinical experience in pig islet transplantation will be actively combined with OPF’s global drug development expertise and these partnerships to further strengthen and expedite the US development program.

This alignment of DOL’s expertise with the US program is part of DOL’s previously announced commitment to focus on the US development and FDA approval of DIABECELL. Once registered in the US, DOL retains a royalty free right to commercialise the FDA approved product in the rest of the world.

And of greater interest, Seeking Alpha says of DOL:

Otsuka is a formidable Japanese company with an established presence for its products in the US. Most notably its Abilify antipsychotic drug (shared with Bristol-Myers Squibb (NYSE:BMY)) generated $6.5 billion in US sales in 2013 (a top 10 US drug). To show it is no shrinking violet, Otsuka is involved in a fight to keep out generic versions of Abilify by suing the FDA!

Here is the press release from OPF.

None of these companies are non-profits and expressly state that they will sell and commercialize this product. They have not requested funding for cure research from the public. 


 

ßAir Bio-Artifical Pancreas

Beta-O2 Technologies

– Tel Aviv, Israel

What it is:

The ßAir Bio-artificial Pancreas is a macrocapsule that contains islets of Langerhans, cells from pancreatic regions of the body that contain hormone-producing beta-cells. The macrocapsule provides a fully isolated environment for the islets to thrive. The islets in the bio-artificial pancreas replace the function of the endocrine part of the pancreas; i.e., the sensing of the level of glucose in the blood and the regulation of the production of insulin and glucagon as needed.

ßAir has the potential to ‘normalize’ the lives of people living today with type 1 diabetes. How? Of greatest importance, the ßAir bio-artificial pancreas eliminates the need for frequent glucose testing and insulin injections. Immunosuppressive therapy, which has many side effects, is also not required.

Note: as the ßAir device contains ‘living’ cells, the patient must commit to keeping them healthy. Once every 24 hours, the patient needs to refill the air in the device using a replenishing device which includes a dedicated injector. This guarantees that the cells will have the requisite oxygen supply to thrive and perform their insulin and glucagon production role.

Replenishing the device is performed by injecting oxygen into one of two ports implanted under the skin. The replenishing device is very user friendly, requires minimal technical skills for operation, and has very few possibilities for incorrect operation. The replenishing procedure takes just about two minutes. An alarm will trigger if something has gone wrong. (Beta O2 Website)

Where it is in the pipeline of “practical cure”:

Phase I/II clinical trial being conducted in Sweden. Last verified in December, 2014 with a study completion date of March, 2016. 8 people are to be enrolled in this study. No results have been reported.

Who is funding this “practical cure”?

JDCA forgets to include this:

JDRF funded this company in 2014 to help get this clinical trial going.

Here’s the list of additional investors. As of this time, there has been no appeal to the general public for donations.


 

My Conclusion from Part 1:

For all the talk about JDRF not helping to fund a “practical cure,” I’m here to show you that JDRF is helping. Perhaps not to the extent that JDCA deems acceptable.

Who is JDCA to determine how much is acceptable?

Their “survey” of 1,000 donors in 2014, conducted by a third party (but where did they get their donor responses? Ask yourself that as they didn’t publicly state it in their report) claims that 88% of donors want their donations to go to “cure research.” The questions were targeted to invoke “cure” responses.

And before you jump on me saying that I’m a shill for JDRF (or ADA, who hasn’t been mentioned by me yet)… be very aware of this fact:

I donate to one of the “practical cures” that JDCA touts.

I’ve asked others for their help in funding this “practical cure.” I also donate to other diabetes non-profits, some big and some small, because I know (from my own thirty-two years of T1 diabetes) that while

I would sell everything I own to have a cure, crawl across a minefield strewn with broken glass to not have this horrible disease haunt me

in the meantime, we need support and research for the complications from this disease.

Every time a parent complains about a school issue in the US, every time a child gets a T1 peer or mentor, every time a teenager goes to a summer camp where diabetes is the norm, every time a family member views their loved one’s BG graph on a device from miles away… those donations matter, too. 

Conclusion: DO. YOUR. OWN. RESEARCH. 

More information is coming in Part 2, including JDCA’s practical cure solutions: devices (1) and immune system modifications(4).

Don’t be surprised. Or disappointed.

I was told in 1983 there would be a cure in five years. I’ve waited this long. We’ll all be waiting a little longer.

* I have chosen not to link to JDCA’s website. On purpose. They’re easy to Google if you want to see what I did. I’ve linked to the deep dive stuff.


 

Got Twitter? Simply click this link to share this post. 

If only everything was that easy.


 

Need Help With U.S. Diabetes Supplies and Medications? UPDATED!

 

159942_2191

This is a current list of currently available programs, co-pay cards, organizations and manufacturers that may help, and the requirements to participate in the programs.

Included in this update is a large expansion in the co-pay card program, which is helpful for individuals with insurance (but high co-pays!). You can now scroll quickly through this list, as medications are now bolded in RED.  It is also separated into insulin/injectable meds and oral meds to help make your medications easier to find. 

These links are up to date as of 23 August 2015. (If you have links or resources, please list them in the comment section and if they’re legitimate, I’ll add them.)

Why did I create this?

Every other “diabetes financial assistance/resource” page that I would visit would give you a link to supposed help – but you had to dig deep to find out if there were exclusions or restrictions. Some of the resource pages had links that no longer exist. Others had a single page that said: “We no longer offer a program.”

This page will give you the restrictions/exclusions I’ve found and the contact information and site to get yourself started if you qualify. (And in some cases, all of us will qualify!)

Hope this helps you.

Share this information – no one should be “sick” with diabetes from a lack of medication or supplies – let’s help each other by getting the word out. 


Got Twitter? Help spread the word easily by clicking here:

Tweet: Need help with U.S. #diabetes supplies and meds? Click here: http://ctt.ec/q2s85+ Includes co-pay help for insulin, oral meds.


 

Insulin, Injectable Diabetes Medication, & Needles

Astra-Zeneca Prescription Savings Program – NO insurance

If you take BYDUREON, BYETTA, or SYMLIN, you may be eligible for free medications mailed to your home or provider. Requirements include:

  • You must be resident of the US, or have a Work Visa or Green Card.
  • You aren’t currently receiving prescription drug coverage under a private insurance or government program, or receiving any other assistance to help pay for medicine.
  • Your annual income* should be at or below:
    • $35,000 for a single person
    • $48,000 for a family of two
    • $60,000 for a family of three
    • $70,000 for a family of four
    • $80,000 for a family of five
      • *Income limits may be higher in Alaska and Hawaii

If you are a Medicare Part D Beneficiary:

  • You aren’t eligible for or enrolled in Limited Income Subsidy (LIS) for Medicare Part D

If you have experienced a life changing event in the past year, and your financial documentation does not accurately reflect your current situation, we encourage you to apply for the AZ&Me Prescription Savings Program. You may still meet the criteria to enroll. Some examples of this type of event would be:

  • Loss of employment
  • Change in income
  • Loss of, or change in, prescription drug coverage
  • Marriage
  • Change in household number

For assistance and additional information, you can call  1-800-AZandMe (292-6363).

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

There is also a MySavingsRX Card for BYDUREON, BYETTA, or SYMLINThe cost would be reduced to $25 per month.

You may be eligible for the Savings Card if:

  • You are insured by commercial insurance and your insurance does not cover the full cost of your prescription, or you are not insured and are responsible for the cost of your prescriptions.
  • Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.
  • You are enrolled in a state or federally funded prescription insurance program, you may not use this Savings Card even if you elect to be processed as an uninsured (cash-paying) patient.
  • You are 18 years of age or older.
  • This offer is not insurance and is restricted to residents of the United States and Puerto Rico.

Eli Lilly – Lilly Cares – NO insurance

Eli Lilly offers Glucagon, Trulicity, Humalog, Humalin, and Humalog Mix under the Lilly Cares program.

  • You must be a U.S. resident. (This program is not available in Puerto Rico or the US Virgin Islands.)
  • You must not have prescription coverage.
  • You must meet the household guidelines:

Household Income Guidelines:

  • The total number of people in the household includes yourself and each of your dependents.
  • Total yearly income includes incomes from all earners in your household before taxes and deductions.
  • To qualify, your total yearly income cannot exceed the values listed below.
Number of People in Your Home 1 2 3 4 5 6 7 8
Total Yearly Income
(48 Contiguous States and DC)
$35,310 $47,790 $60,270 $72,750 $85,230 $97,710 $110,190 $122,670
Alaska $44,160 $59,760 $75,360 $90,960 $106,560 $122,160 $137,760 $153,360
Hawaii $40,650 $54,990 $69,330 $83,670 $98,010 $112,350 $126,690 $141,030

For additional information about Lilly Cares, call at 1-800-545-6962.

*A 120-day supply of medicine will be shipped to your health care provider’s office. Prescription refills will be available during your 1-year enrollment period.

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

There is a Prescription Copay Card for the Humalog U-200 Kwikpen, but you must ask your physician for it. You must have commercial insurance through your employer or independent insurance that is not a government-sponsored plan (for example, Medicaid or Medicare).  If eligible, you’ll pay as little as $25 for your prescription.

Trulicity has a savings card, giving you this medication for $25 per month for up to two years. You must meet the following criteria:

  • 18 or older and currently living in the United States or Puerto Rico.
  • Have commercial health insurance (insurance other than Medicare, Medicaid, etc)
  • Not have your prescription paid in part or full by any government funded program, including but not limited to, Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE® or any State Patient or Pharmaceutical Assistance Program.
  • This offer is invalid for patients without commercial insurance coverage.

Eli Lilly Lilly MedicareAnswers

For those individuals on Medicare, you have an option!

Eli Lilly offers Glucagon, Trulicity,  Humalog, Humalin, and Humalog Mix under the Eli Lilly LillyMedicareAnswers program.

  • You must be enrolled in a Medicare Part D prescription plan.
  • You must be denied or ineligible for Low Income Subsidy.
  • You must be a United States resident.(This program includes Puerto Rico.)
  • You must meet the household guidelines:

Household Income Guidelines:

  • The total number of people in the household includes yourself and each of your dependents.
  • Total yearly income includes incomes from all earners in your household before taxes and deductions.
  • To qualify, your total yearly income cannot exceed the values listed below.
Number of People in Your Home 1 2 3 4 5 6 7 8
Total Yearly Income
(48 Contiguous States and DC)
$35,310 $47,790 $60,270 $72,750 $85,230 $97,710 $110,190 $122,670
Alaska $44,160 $59,760 $75,360 $90,960 $106,560 $122,160 $137,760 $153,360
Hawaii $40,650 $54,990 $69,330 $83,670 $98,010 $112,350 $126,690 $141,030

*A 90-day supply of medicine will be shipped to your home via mail order pharmacy. Prescription refills will be available during your 1-year enrollment period.

NovoNordisk – NO insurance

Novo Nordisk Patient Assistance Program (PAP) provides free medicine (to those who qualify), including: Levemir, Novolog, Novolog Mix 70/30, Novolin, GlucaGen Hypo Kit, Victoza, and disposable needles for FlexPens and Victoza. (Please be aware that all insulin is vial only; no FlexPens.)

The application for Novo Nordisk’s medication assistance program is downloadable here. 

  • There are several restrictions to the program. Please download the application and review.
  • You must be a U.S. citizen.
  • You must have a household income less than 200% of federal poverty level. 200% FPL* $47,700
  • You cannot have private prescription coverage,VA prescription benefits, any federal, state, or local program such as Medicare or Medicaid. Exceptions include patients who have entered the coverage gap (donut hole) in Medicare Part D and patients who have applied for and been denied Medicare Extra Help/Low Income Subsidy (LIS) and are Medicare eligible.

You can get more information by calling the Novo Nordisk Patient Assistance Program toll free at 866-310-7549.

If approved, a free 120-day supply of medicine will be sent to the prescribing health care providers’ office to be picked up at the patient’s convenience. Novo Nordisk will automatically contact the health care provider 90 days later to approve the medication reorder.

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

There is an Instant Savings Card for Victoza, which brings the cost to $25 per monthly prescription for up to 2 years.

The Instant Savings Card is not valid for prescriptions purchased under Medicaid, Medicare, or similar federal, state, or government-funded benefit programs. This includes Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, as well as any other state or federal employee benefit programs.

There is an Instant Savings Card for Levemir. If eligible, you will pay no more than $25 for your Levemir® prescription and each refill for up to 2 yearsa with a Novo Nordisk Instant Savings Card. The savings card can be used like a coupon when you pick up your Levemir® prescription from the pharmacy.

In addition, pay no more than $20 (maximum savings up to $100 per fill) for the next prescribed product and each refill for up to 2 years. Offer available for a 30-day supply of Victoza® (liraglutide [rDNA origin] injection), Levemir® (insulin detemir [rDNA origin] injection), NovoLog® (insulin aspart [rDNA origin] injection), and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart, [rDNA origin] injection). Offer is valid for a maximum of $100 off your co-pay for each 30-day supply of Victoza®, Levemir®, NovoLog®, and NovoLog® Mix 70/30. Offer is valid for a maximum of 24 refills per product over 2 years. Novo Nordisk reserves the right to modify or cancel this program at any time.

There is also a  Novo Nordisk prescription savings card for other products: Offer available for a 30-day supply of Levemir® FlexPen, NovoLog® Mix 70/30 FlexPen, and NovoLog. Like the other prescription savings cards, it has restrictions, but these also give $25 per month prescription savings.

Sanofi Patient Connection Program– NO insurance

Provides Apidra, Lantus, and Toujeo at no cost to patients who meet program eligibility requirements.

Eligibility requirements include:

  • Patient must be a U.S. citizen or resident and be under the care of a licensed healthcare provider authorized to prescribe, dispense and administer medicine in the U.S.
  • Patient must have no insurance coverage or no access to the prescribed product or treatment via their insurance
  • Patient must not be eligible for Medicare or Medicaid
    • See program application for Medicare Part D eligibility criteria
  • Patient must meet the following financial criteria:
    • Annual household income of ≤250% of the current Federal Poverty Level for all non-Oncology/non-Hematology Products
Persons in family / household Poverty Guideline 2015* Maximum Annual Household Income (for uninsured or functionally uninsured patients)
250%
1 $11,770 $29,425
2 $15,930 $39,825
3 $20,090 $50,225
4 $24,250 $60,625
5 $28,410 $71,025
6 $32,570 $81,425
7 $36,730 $91,825
8 $40,890 $102,225
For families / households with more than 8 persons, add $4,160 for each individual person All products except Oncology / Hematology

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

Apidra

Those who take Apidra can use the Apidra® No Co-Pay Savings Program with their Apidra® prescription payments. Activate your card by checking this box and you can get No Co-Pay* on Apidra®. If you’re registering someone under the age of 18, please call 855-242-6938.

  • The card is not valid for prescriptions purchased under Medicaid, Medicare, or similar federal, state, or other government funded benefit programs.
  • Only patients who reside in the United States or Puerto Rico can participate in this program.
  • All commercially insured patients are eligible, even those with insurance that places Apidra® on the 3rd tier.
  • Cash-paying patients are also eligible for a benefit of up to $100 off per prescription.

Lantus

Sanofi offers a discount card for those who use Lantus SoloStar – pay no more than $25 for up to 3 prescriptions. (Maximum $100 benefit off of each prescription, for up to $300 for three prescriptions.)

  • The card is not valid for prescriptions purchased under Medicaid, Medicare, or similar federal, state, or other government funded benefit programs.
  • Only patients who reside in the United States or Puerto Rico can participate in this program.
  • All commercially insured patients are eligible.

Toujeo

Pay no more than $15 for the 12 months after activating the savings program. (Maximum benefit is $400 off per prescription depending on your out of pocket costs.)

  • The card is not valid for prescriptions purchased under Medicaid, Medicare, or similar federal, state, or other government funded benefit programs.
  • Only patients who reside in the United States or Puerto Rico can participate in this program.
  • All commercially insured patients are eligible.

Afrezza

With the Afrezza Patient Savings Card, you pay $0 for your first prescription. After that you pay no more than $30 for each prescription refill, depending on your insurance coverage. With each prescription, you get 2 inhalers and a month’s supply of Afrezza® cartridges.

  • Offer is not valid for patients if their prescriptions are paid in part or in full by any state or federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA, DOD or TriCare.
  • Only patients who reside in the United States, Puerto Rico, Guam or the US Virgin Islands can participate in this program.
  • If you have any questions about this program, please call 866-991-2840.

Diabetes Oral Medications

Astra-Zeneca Prescription Savings Program– NO insurance

If you take FARXIGA, KOMBIGLYZE XR, ONGLYZA, or XIGDUO XR, you may be eligible for free medications mailed to your home or provider. Requirements include:

  • You must be resident of the US, or have a Work Visa or Green Card.
  • You aren’t currently receiving prescription drug coverage under a private insurance or government program, or receiving any other assistance to help pay for medicine.
  • Your annual income* should be at or below:
    • $35,000 for a single person
    • $48,000 for a family of two
    • $60,000 for a family of three
    • $70,000 for a family of four
    • $80,000 for a family of five
      • *Income limits may be higher in Alaska and Hawaii

If you are a Medicare Part D Beneficiary:

  • You aren’t eligible for or enrolled in Limited Income Subsidy (LIS) for Medicare Part D

If you have experienced a life changing event in the past year, and your financial documentation does not accurately reflect your current situation, we encourage you to apply for the AZ&Me Prescription Savings Program. You may still meet the criteria to enroll. Some examples of this type of event would be:

  • Loss of employment
  • Change in income
  • Loss of, or change in, prescription drug coverage
  • Marriage
  • Change in household number

For assistance and additional information, you can call  1-800-AZandMe (292-6363).

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

Farxiga and Xigduo XR have a prescription Savings Card that can be $0 per month as long as your physician prescribes a dose of either medication.

You may be eligible for the Savings Card if:

  • You are insured by commercial insurance and your insurance does not cover the full cost of your prescription, or you are not insured and are responsible for the cost of your prescriptions.
  • Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.
  • You are enrolled in a state or federally funded prescription insurance program, you may not use this Savings Card even if you elect to be processed as an uninsured (cash-paying) patient.
  • You are 18 years of age or older.
  • This offer is not insurance and is restricted to residents of the United States and Puerto Rico.

Onglyza and Kombiglyze XR has a prescription savings card as well that can be $0 per month.

You may be eligible for the Savings Card if:

  • You are insured by commercial insurance and your insurance does not cover the full cost of your prescription, or you are not insured and are responsible for the cost of your prescriptions.
  • Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.
  • You are enrolled in a state or federally funded prescription insurance program, you may not use this Savings Card even if you elect to be processed as an uninsured (cash-paying) patient.
  • You are 18 years of age or older.
  • This offer is not insurance and is restricted to residents of the United States and Puerto Rico.

Eli Lilly – Lilly Cares – NO insurance

Eli Lilly offers Cymbalta under the Lilly Cares program.

  • You must be a U.S. resident. (This program is not available in Puerto Rico or the US Virgin Islands.)
  • You must not have prescription coverage.
  • You must meet the household guidelines:

Household Income Guidelines:

  • The total number of people in the household includes yourself and each of your dependents.
  • Total yearly income includes incomes from all earners in your household before taxes and deductions.
  • To qualify, your total yearly income cannot exceed the values listed below.

 

Number of People in Your Home 1 2 3 4 5 6 7 8
Total Yearly Income
(48 Contiguous States and DC)
$35,310 $47,790 $60,270 $72,750 $85,230 $97,710 $110,190 $122,670
Alaska $44,160 $59,760 $75,360 $90,960 $106,560 $122,160 $137,760 $153,360
Hawaii $40,650 $54,990 $69,330 $83,670 $98,010 $112,350 $126,690 $141,030

For additional information about Lilly Cares, call at 1-800-545-6962.

*A 120-day supply of medicine will be shipped to your health care provider’s office. Prescription refills will be available during your 1-year enrollment period.

Boehringer Ingelheim Cares Patient Assistance Program – NO insurance

Tradjenta, Jentadueto, Jardiance, and Glyxambi are available under the BI Cares Patient Assistance Program.

  • You must be a U.S. resident ineligible for private prescription, Medicaid, or Low Income Subsidy coverage.
  • You must meet the established financial criteria, which was not posted online.
  • You must be 18 years of age or older. Please note, while people of all ages are eligible for the program, applications can be sent only to people at least 18 years of age.

Medication is shipped directly to the patient’s home.

Applications are evaluated on a case by case basis. Current application form, valid prescription, and patient’s income documentation are required.To learn more about the Boehringer Ingelheim Patient Assistance Program, please call 1-800-556-8317 or apply online at www.bipatientassistance.com.

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

Trajenta has a prescription savings card, which can drop the price for your prescription to as little as $10 per month. Eligible patients 18 years or older may pay as little as $10/month with a maximum savings up to $150/monthly prescription.  Only valid for commercially insured patients in the 50 United States, DC, and Puerto Rico. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or TRICARE and where prohibited by law. Offer may change at any time, without notice.

Jentadueto also has a prescription savings card, which can drop the price for your prescription to as little as $10 per month. Eligible patients 18 years or older may pay as little as $10/month with a maximum savings up to $150/monthly prescription.  Only valid for commercially insured patients in the 50 United States, DC, and Puerto Rico. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or TRICARE and where prohibited by law. Offer may change at any time, without notice.

Jardiance also has a prescription savings card – eligible patients get their first year’s prescription FREE. Eligible patients 18 years or older may pay as little as $0/month with a maximum savings up to $384/monthly prescription. Only valid for commercially insured patients in the 50 United States, DC, and Puerto Rico. Not eligible if prescriptions are paid for in part/whole by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or TRICARE.

Glyxambi also has a prescription savings card and eligible patients get their first year’s prescription FREE. Eligible patients 18 years or older may pay as little as $0/month with a maximum savings up to $538/monthly prescription. Only valid for commercially insured patients in the 50 United States, DC, and Puerto Rico. Not eligible if prescriptions are paid for in part/whole by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or TRICARE. Offer may change at any time, without notice.

GlaxoSmithKline – NO insurance

Avandia is available under the Bridges to Access Program for individuals not on Medicare.

To qualify for Bridges To Access, patients must:

  • Live in one of the 50 states, District of Columbia or Puerto Rico.
  • Have no prescription drug benefits through any insurer/payer/program.
  • Not be eligible for Medicaid or Puerto Rico’s Government Health Plan Mi Salud. Puerto Rico applicants who are financially eligible for Puerto Rico’s Government Health Plan must have documentation of denial of coverage through Mi Salud before applying to a GSK Patient Assistance Program.
  • Have gross monthly household income at or below the following:
Maximum Monthly Gross Income
Household Size 
48 states and D.C.
Alaska
Hawaii
Puerto Rico
1
$2,452.08
$3,066.67
$2,822.92
$2,000.00
2
$3,318.75
$4,150.00
$3,818.75
$2,500.00
3
$4,185.42
$5,233.33
$4,814.58
$3,000.00
4
$5,052.09
$6,316.66
$5,810.41
$3,500.00
For each additional person, add
$866.67
$1,083.33
$995.83
$500.00

You can apply by mail or fax (proof of income must be provided), or call Bridges to Access at 1-866-PATIENT (1-866-728-4368) after downloading the application.

If you are on Medicare and have a Part D prescription plan, you may be able to receive Avandia through GSK Access.

To qualify for GSK Access and enroll, you must:

  • Be enrolled in a Medicare Part D Prescription Drug Plan.
  • Have spent at least $600 on prescription medicines through their Medicare Part D Prescription Drug Plan during this calendar year.
  • Live in one of the 50 states, District of Columbia or Puerto Rico. Puerto Rico applicants who are financially eligible for Puerto Rico’s Government Health Plan must have documentation of denial of coverage through Mi Salud before applying to a GSK Patient Assistance Program.
  • Have total monthly household income at or below the following:
Maximum Monthly Gross Income
Household Size 
48 states and D.C.
Alaska
Hawaii
Puerto Rico
1
$2,452.08
$3,066.67
$2,822.92
$2,000.00
2
$3,318.75
$4,150.00
$3,818.75
$2,500.00
3
$4,185.42
$5,233.33
$4,814.58
$3,000.00
4
$5,052.09
$6,316.66
$5,810.41
$3,500.00
For each additional person, add
$866.67
$1,083.33
$995.83
$500.00

Upon initial enrollment in GSK Access and with a valid prescription on file, the first 90-day supply of GlaxoSmithKline medicine(s) will be shipped to the address provided on the application. (Some medicines are only available at a retail pharmacy. Patients will be notified if their prescription is for one of these medicines.) Medicines received from this program do not count toward True Out-of-Pocket Spending Costs (TrOOP).

Fill out this application online, download and add documentation to send or fax. If you have questions about this program, call 1-866-518-HELP.

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

Tanzeum Coupons, up to 12 months free.

Tanzeum, a GSK product, has a “dollars off” coupon program. Coupon program eligibility is extended to patients with or without insurance coverage with a valid signed prescription.

  • You are NOT eligible to use this coupon if you are a government beneficiary. You are a government beneficiary if you are enrolled in any federal healthcare program, including Medicaid, Medicare (Part D or otherwise), or any similar federal or state programs, including any state pharmaceutical assistance program. Further, you CANNOT use this coupon if you are Medicare eligible.

Eligible patients without insurance can receive the dollars off amount specified on the coupon. Patients with insurance can receive up to the amount for which they are responsible for the prescription, less any amounts specified on the coupon.

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

Invokana or Invokamet CarePath Savings Program

This program offers 12 months of prescription co-pay relief (According to Invoking CarePath’s marketing material “12 months NO COST to you” for those who have been prescribed Invokana or Invokamet.) You must have commercial insurance.

After registering, you receive a savings card that you use at your retail pharmacy. It is subject to a $4,600 annual program benefit, 12 months after activation or 12 uses, whichever comes first. It is not valid for those enrolled in Medicare Part D or Medicaid, or those enrolled in a federal or state subsidized healthcare program that covers prescription drugs such as TRICARE. The offer is only valid for new enrollment until December 31, 2016.

Johnson & Johnson Patient Assistance Program– NO insurance

If you do not have prescription coverage, you may be eligible to receive Invokana or Invokamet through the Johnson & Johnson Patient Assistance Program.

Requirements are:

  • You do not have public or private prescription coverage.
  • You reside in the U.S. or a U.S. territory.
  • You are being treated as an outpatient by a U.S. healthcare provider.
  • You meet annual financial eligibility criteria:
    • Single person: $23,540 annual income or less
    • Two person family: $31,860 or less
    • Larger families: income levels are adjusted “accordingly”

You can begin the application process online by clicking here or by calling 1-800-652-6227.

Merck Helps – NO insurance

Merck Patient Assistance Program

Merck offers a prescription assistance program for Januvia, Janumet, and Janumet XR.

  • You do not have to be a US citizen. Legal residents of the United States, including US Territories, are also eligible.
  • Your prescription for a Merck medicine from a health care provider licensed in the United States.*
  • You do not have insurance or other coverage for your prescription medicine. Some examples of other insurance coverage include private insurance, HMOs, Medicaid, Medicare, state pharmacy assistance programs, veterans assistance, or any other social service agency support.
  • You may qualify for the program if you have a household income of $47,080 or less for individuals, $63,720 or less for couples, or $97,000 or less for a family of 4.

The application for this program must be downloaded, filled out, and brought to your medical provider. Click here for the Merck Helps application.  (It is also available in Spanish.)

Individuals who don’t meet the insurance criteria may still qualify for the Merck Patient Assistance Program if they attest that they have special circumstances of financial and medical hardship, and their income meets the program criteria. A single application may provide for up to 1 year of medicine free of charge to eligible individuals and an individual may reapply as many times as needed.

If you have any questions about the Merck Patient Assistance Program including the status of an application, please call 1-800-727-5400, 8 AM to 8 PM EST, Monday through Friday.

There is also the ACT Program. The ACT Program provides free reimbursement support services to help answer questions related to insurance coverage and reimbursement. If you do not meet the prescription drug coverage criteria, your income meets the program criteria, and there are special circumstances of financial and medical hardship that apply to your situation, you can request that an exception be made for you. If you have any questions, the ACT Program Specialists are available 8 AM to 8 PM EST, Monday through Friday at 1-866-363-6379.

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

If you don’t meet the criteria, you can also try and use the “Januvia copay assistance coupon”. 

Januvia’s coupon is for “as little as $5 per prescription” for up to 12 months. Here’s the information on the restrictions and what you’d need to do. 

CO-PAY Savings Card –  Private/Commercial Insurance Coverage Help

Pfizer

If you use Glucotrol, Glynase Prestab, Glyset, and Lyrica, Pfizer offers a discount card for individuals who have NO prescription coverage. You’ll need to call 866-706-2400 to apply. 

  • You must be prescribed a Pfizer medicine available at a savings.
  • Have no prescription coverage.
  • Live in the United States, Puerto Rico, or the U.S. Virgin Islands

They also offer free medication for uninsured individuals through some clinics and hospitals. You can see if there is one located near you by entering your zip code at this website

Lyrica Co-Pay Savings Card

Lyrica Co-pay of $25 per month up to 12 months. There are restrictions, but worth checking out and downloading. 

Other Savings Programs

Patient Access Network Foundation

The Patient Access Network (PAN) Foundation, an independent, national 501 (c)(3) organization dedicated to providing underinsured patients with co-payment assistance through more than 60 disease-specific programs that give them access to the treatments they need.

Diabetic Foot Ulcers

Eligibility Criteria

  •  Patient should be insured and insurance must cover the medication for which patient seeks assistance.
  •  The medication must treat the disease directly.
  •  Patient must reside and receive treatment in the United States.
  •  Patient’s income must fall below 400% of the Federal Poverty Level. (Here’s the handy chart showing you what that is based on how many people are in your household.)

Diabetic Macular Edema

Eligibility Criteria

  •  Patient should be insured and insurance must cover the medication for which patient seeks assistance.
  •  The medication must fight the disease directly.
  •  Patient must reside and receive treatment in the United States.
  •  Patient’s income must fall below 500% of the Federal Poverty Level. (You can use the chart and do the calculations for 500%. For instance, if you are a household of one, you qualify if you earn less than $48,350 gross income annually. For a household of three, you qualify if the household earns less than $98,950.)

Kidney Transplant Immunosuppressants 

Eligibility Criteria

  •  Patient should be insured and insurance must cover the medication for which patient seeks assistance.
  •  The medication must fight the disease directly.
  •  Patient must reside and receive treatment in the United States.
  •  Patient’s income must fall below 500% of the Federal Poverty Level. (You can use the chart and do the calculations for 500%. For instance, if you are a household of one, you qualify if you earn less than $48,350 gross income annually. For a household of three, you qualify if the household earns less than $98,950.)

Solid Organ Transplant Immunosuppressant Therapy

This will cover pancreas transplants and kidney-pancreas transplants.

Eligibility Criteria

  •  Patient should be insured and insurance must cover the medication for which patient seeks assistance.
  •  The medication must treat the disease directly.
  •  Patient must reside and receive treatment in the United States.
  •  Patient’s income must fall below 400% of the Federal Poverty Level. (Here’s the handy chart showing you what that is based on how many people are in your household.)

Retinal Vein Occlusion (RVO)

From the Patient Access Network Foundation website:

Central and branch retinal vein occulusions (RVO) happen when the vein at the back of the eye is blocked. This blockage causes pressure build and some of the small blood vessels in the eye may burst and cause fluid to leak into the retina. If untreated the vessels may be able to repair themselves and bypass the blockage but there may be permanent damage to the retina resulting in vision loss. 

Eligibility Criteria

  •  Patient should be insured and insurance must cover the medication for which patient seeks assistance.
  •  The medication must fight the disease directly.
  •  Patient must reside and receive treatment in the United States.
  •  Patient’s income must fall below 500% of the Federal Poverty Level. (You can use the chart and do the calculations for 500%. For instance, if you are a household of one, you qualify if you earn less than $48,350 gross income annually. For a household of three, you qualify if the household earns less than $98,950.)

 

Healthwell Foundation

For children under eighteen years of age

HealthWell Pediatric Assistance Fund® assists children 18 years old or younger living with a chronic or life-altering condition that their families are struggling to treat due to cost. They provide financial assistance to families so their children can start or continue critical medical treatments, including diabetes.

Families must meet HealthWell’s standard income and insurance eligibility criteria to qualify for a grant. Grants are awarded on a case by case basis. To apply for a grant, call 1-800-675-8416 anytime Monday through Friday, 9:00 a.m. to 5:00 p.m. (ET).

  • You must have some form of health insurance (major medical or prescription drug) that covers part of the cost of your medication.
  • Families with incomes up to 400 percent of the Federal Poverty Level may qualify. HealthWell also considers the cost of living in a particular city or state.
  • If you appear to be eligible for assistance through the Pediatric Assistance Fund, additional information and documentation is required for review and consideration prior to grant approval. Once all information has been received and reviewed by the committee, grant determinations will be made.
  • You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.

Immunosuppressive Treatment for Solid Organ Transplant Recipients

HealthWell will pay for the following medications for immunosuppressive therapy:

Astagraf XL, Cellcept, Gengraf, Hecoria, Imuran, Myfortic, Neoral, Nulojix, Prograf, Rapamune, Sandimmune, and Zortress.

  • You must have some form of health insurance (major medical or prescription drug) that covers part of the cost of your medication.
  • Families with incomes up to 400 percent of the Federal Poverty Level may qualify. HealthWell also considers the cost of living in a particular city or state.

You can apply online for this medication grant here.  or call 800-675-8416. Agents are available Monday–Friday 9am–5pm EST.

Insulin Pumps

Please be aware that many insulin pump companies do not offer charitable or financial assistance to obtain insulin pumps or supplies. If you find yourself without the financial means to continue on insulin pump therapy, contact your medical team right away for alternatives.

Medtronic MiniMed

The Medtronic Financial Assistance Program offers help to those who:

  • Use an insulin pump and/or continuous glucose monitoring
  • Meet specific income guidelines
  • Have an insurance company that allows for additional assistance

It also provides temporary coverage for specific situations:

  • Unemployment within the last 12 months
  • Gap in insurance coverage because of a pre-existing condition
  • Multiple pumpers in one household
  • Permanent disability

You’ll need to call Medtronic 1-800-646-4633 and select option 4 to get specific information.

Other pump companies offer self-funding payment programs. You should call them individually to find out the particulars. (The plans may change based on what you are looking for…)

*** If you have information regarding insulin pump programs, please contact me via email at theperfectd [at] gmail.com – you’ll be helping us all out!***

Equipment

Charles Ray III Diabetes Association

The CR3 Diabetes Association, Inc. is a 501(c)3 non-profit organization. 

According to the website, the organization is currently accepting applications for insulin pumps, blood glucose meters, and blood glucose test strips. You must review the following criteria:

  • You are uninsured
  • You are under insured (which means that your yearly deductible is unattainable)
  • Household income is less than $60,000
  • Your physician has recommended insulin pump therapy for you

They will only accept online applications on their website. The link to the online application is here.

Supplies for CWD Foundation (For children aged 18 years and younger)

Supplies for CWD Foundation (SCWDF) is a branch of the Children with Diabetes Foundation, a non-profit 501(c)(3) organization, providing short-term (up to three months) diabetes supplies for children with type 1 diabetes who are in emergency situations. (An emergency situation may be defined as: loss of health insurance, loss of a parent’s job, or a local disaster, combined with the family having no other resources with which to purchase diabetes supplies.)

Diabetes supplies is defined as any of the following: blood glucose meter, blood glucose test strips, insulin, insulin pump supplies, blood or urine ketone strips, lancets, syringes, and glucose tablets.

Download and fill out this application after reviewing all the requirements on the website.

Blood Glucose Meters/Test Strips

Freestyle Promise Program – $15 copays and a free Abbott Freestyle meter.

  • Co-pay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs or in Massachusetts.
  • Eligible patients are responsible for the first $15 of co-pay under their insurance coverage, and can receive up to a maximum of $50 in co-pay savings. Uninsured patients are also eligible for savings in most situations.

Contour Choice Program – For ContourNext test strips. Eligible patients pay the first $15 in co-pays each month. Insured patients can receive savings of up to $35 per month of co-pays using the Contour Choice Card.

Not valid for patients with prescription benefits covered by federal and/or state government programs (e.g. Medicare, Medicaid.)

Free Meter Offers

Accu-Chek Nano or Aviva

One Touch Verio or Verio IQ Meter

Low Cost Meter/Strips Offers

Abott Neo Coupon Offer – The Neo is a low-cost meter and strips option, often costing less than co-pay prescriptions.

Clinical Trials

Do not forget about participating in clinical trials, some of which provide monetary compensation in addition to supplies and medications at no cost. (Some also provide physician/medical visits!)

Please seriously consider participating in these trials – in some, you can get access to pumps or medications that would not be available to you due to cost – or FDA approval. And… you can help others (and yourself) through clinical trials.

Click here for a list of clinical trials for diabetes that are recruiting  (general, which include both Type 1, Type 2, LADA, MODY, and gestational).

Any other sites/supplies/organizations/medication programs that might be helpful to others? Help us!


Got Twitter? Help spread the word easily by clicking here:

Tweet: Need help with U.S. #diabetes supplies and meds? Click here: http://ctt.ec/q2s85+ Includes co-pay help for insulin, oral meds.


 

DPAC – Diabetes Patient Advocacy Coalition: Why?

Your day just got a little more exciting.

Why?

WE_ARE_DPAC-03

You can make a difference…in not just your life, but the lives of 29 million Americans and their families, friends, and employers.

Wait! Don’t sip your coffee and click to the next tab on your browser. (Sip your coffee and keep reading.)

If you are like I was (not too long ago), the thought of diabetes advocacy was simply this:

“Like I have time. Someone else will do all the hard work. Whatever.”

Now…

  • What if I told you that someone did all that hard work for you?
  • That advocating for yourself, people you love, heck… anyone in the U.S. with diabetes is now simple, easy, and quick?
  • One website to learn about the issues impacting people with diabetes being decided by lawmakers and governmental agencies and then tell them quickly how you feel?
  • A few clicks and you’re done, but you’ve helped the diabetes community and become a diabetes advocate?

Allow me to introduce the Diabetes Patient Advocacy Coalition (DPAC) and invite you to join me and others who care about our community.

WE_ARE_DPAC-01
Who is DPAC? You are. I am. We all are.

 

DPAC is a non-profit and non-partisan organization founded to provide united, simple, and effective advocacy opportunities for people impacted by diabetes for safety, quality and accessibility of care.

And there is no cost to be a part of it.

Sign up and take action immediately from the comfort of your keyboard. You won’t have to figure out who your government representatives are or how to contact them – it’s done for you. After you quickly learn why it’s important to let them know how you feel on a diabetes issue, you just… Click. Click. Done.

I don’t think I’ve ever met anyone who said: “I’d like to spend my day reading over proposed legislation and policy all day.” I certainly don’t. DPAC does that for you, boiling it down to the key points that you need to know.

Why?

Why bother to join? Have you ever been to a concert where the booming sound from the speakers drowns out a conversation you’re trying to have with your friend? One conversation gets lost sometimes.

Have you ever been to a concert where the singers asks the crowd to belt out the chorus of a song? When everyone is raising their voices as one… the whole audience is heard. That booming sound comes from the people in the crowd. We are that crowd.

The diabetes community deserves to be heard by our policymakers as a united voice. 

Why?

1434784_54457950Why join the Diabetes Patient Advocacy Coalition? I already do stuff with other diabetes organizations, you say. How is DPAC different, you say?

DPAC will keep policy makers’ attention on people with diabetes. Diabetes advocacy is like diabetes care; both are long-term processes with no quick fixes. 

Every diabetes organization has a mission; sometimes the mission and the issues that need to be addressed don’t align. Organizations may support one bill and not another – and that’s fine! Some wonderful diabetes organizations are constrained by their non-profit structure, preventing lobbying or the type of advocacy that pierces the heart of the matter.

DPAC is pro-diabetes, pro-existing organizations, pro-getting our diabetes voices heard by policymakers – and that’s the sole focus. Where there is already a movement by one wonderful organization, DPAC adds to the swell. Where an issue is not being given the spotlight, DPAC will shine the light. DPAC doesn’t want to re-invent the wheel; they want the wheel to go faster and gather steam.

If you’ve heard me mumbling over the past few months about a project that I’ve been working on… this is it, along with Bennet Dunlap and some pretty fantastic people and organizations. I’m all about making diabetes advocacy easy – and now it is.

Help raise a united diabetes voice and become part of DPAC. Come join me.